Guinea-Bissau vs Syria: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Guinea-Bissau
2.7%
in 2024
Syria
2.9%
in 2024
Guinea-Bissau rank
9th
Syria rank
6th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Guinea-Bissau
- Syria
How they compare
Syria currently reports 2.9% against 2.7% in Guinea-Bissau, a difference of 0.2%.
That makes Syria's figure about 1.1 times Guinea-Bissau's.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Guinea-Bissau ahead.
Guinea-Bissau ranks 9th and Syria ranks 6th of 247 countries.
Syria has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guinea-Bissau | Syria | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2.8% | 3.5% | 0.7% | Syria |
| 2020s | 2.7% | 3.4% | 0.7% | Syria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Guinea-Bissau or Syria?
- Syria, at 2.9% against 2.7% in Guinea-Bissau as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Guinea-Bissau and Syria?
- 0.2%, with Syria ahead.
- How many years of comparable data are there for Guinea-Bissau and Syria?
- 10 years are reported by both, from 2015 to 2024.
- How do Guinea-Bissau and Syria rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Guinea-Bissau ranks 9th and Syria ranks 6th of 247 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.